Rain Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Rain Oncology

10/08/2021 14:12

* Rain Therapeutics Inc  RAIN.OQ  reported a quarterly adjusted
loss of 39 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 60 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Rain Therapeutics Inc's reported EPS for the quarter was a
loss of 39 cents​.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Rain Therapeutics Inc shares had risen by 4.3% this quarter.
* The company reported a quarterly loss of $8.18 million.
* Wall Street's median 12-month price target for Rain
Therapeutics Inc is $27.00 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated August 10 at 01:12 p.m.  ​All
figures in US dollars unless otherwise stated